Crizotinib

Drug Profile

Crizotinib

Alternative Names: PF-002341066; PF-02341066; PF-1066; PF-2341066; Xalkori

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator Pfizer
  • Developer Astellas Pharma; Dana-Farber Cancer Institute; National Cancer Institute (USA); OxOnc Development; Pfizer; University of Milan Bicocca
  • Class Antineoplastics; Chlorobenzenes; Fluorobenzenes; Piperidines; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Proto oncogene protein c met inhibitors; ROS1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Bladder cancer; Non-Hodgkin's lymphoma; Renal cell carcinoma
  • Phase I Glioblastoma; Prostate cancer; Solid tumours

Most Recent Events

  • 31 Aug 2016 The European Commission approves crizotinib for Non-small cell lung cancer (Late-stage disease, ROS1-positive) in European Union
  • 21 Jul 2016 The Committee for Medicinal Products for Human Use recommends approval of crizotinib for Non-small cell lung cancer (Late stage disease, ROS1-positive) in European Union
  • 01 Jul 2016 Pfizer plans an expanded-access programme for Non-small cell lung cancer in Japan (NCT02824094)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top